Ward L.M., Weber D.R., Munns C.F., Högler W., Zemel B.S. A contemporary view of the definition and diagnosis of osteoporosis in children and adolescents. J. Clin. Endocrinol. Metab. 2020; 105(5): e2088-97. https://doi.org/10.1210/clinem/dgz294
Sakai T., Honzawa S., Kaga M., Iwasaki Y., Masuyama T. Osteoporosis pathology in people with severe motor and intellectual disability. Brain Dev. 2020; 42(3): 256-63. https://doi.org/10.1016/j.braindev.2019.12.010
Yaşar E., Adigüzel E., Arslan M., Matthews D.J. Basics of bone metabolism and osteoporosis in common pediatric neuromuscular disabilities. Eur. J. Paediatr. Neurol. 2018; 22(1): 17-26. https://doi.org/10.1016/j.ejpn.2017.08.001
Gulati S., Sondhi V. Cerebral palsy: an overview. Indian J. Pediatr. 2018; 85(11): 1006-16. https://doi.org/10.1007/s12098-017-2475-1
Henderson R.C., Lark R.K., Gurka M.J., Worley G., Fung E.B., Conaway M., et al. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics. 2002; 110(1 Pt. 1): e5. https://doi.org/10.1542/peds.110.1.e5
Henderson R.C., Kairalla J.A., Barrington J.W. Longitudinal changes in bone density in children and adolescents with moderate to severe cerebral palsy. J. Pediatr. 2005; 146(6): 769-75. https://doi.org/10.1016/j.jpeds.2005.02.024
Галашевская А.А., Почкайло А.С. Современные подходы к лечению и профилактике остеопороза у детей с детским церебральным параличом. Педиатрия. Восточная Европа. 2021; 9(1): 94-106. https://doi.org/10.34883/PI.2021.9.1.008
Крохина К.Н., Смирнов И.Е., Кучеренко А.Г., Беляева И.А. Динамика маркеров остеогенеза у новорожденных детей в норме и при патологии. Вопросы диагностики в педиатрии. 2011; 3(4): 25-31.
Крохина К.Н., Смирнов И.Е., Беляева И.А. Особенности формирования костной ткани у новорожденных детей. Российский педиатрический журнал. 2010; (5): 36-41.
Смирнов И.Е., Крохина К.Н., Кучеренко А.Г., Зайниддинова Р.С., Беляева И.А. Маркеры остеогенеза у новорожденных детей в норме и при патологии. Российский педиатрический журнал. 2011; (5): 13-8.
Leal-Martínez F., Franco D., Peña-Ruiz A., Castro-Silva F., Escudero-Espinosa A.A., Rolón Lacarrier O.G., et al. Effect of a nutritional support system (diet and supplements) for improving gross motor function in cerebral palsy: an exploratory randomized controlled clinical trial. Foods. 2020; 9(10): 1449. https://doi.org/10.3390/foods9101449
Sellier E., Uldall P., Calado E., Sigurdardottir S., Torrioli M., Platt M. Epilepsy and cerebral palsy: characteristics and trends in children born in 1976-1998. Eur. J. Paediatr. Neurol. 2012; 16(1): 48-55. https://doi.org/10.1016/j.ejpn.2011.10.003
Petty S., Wilding H., Wark J. Osteoporosis associated with epilepsy and the use of anti-epileptics - a review. Curr. Osteoporos. Rep. 2016; 14(2): 54-65. https://doi.org/10.1007/s11914-016-0302-7
Ko A., Kong J., Samadov F., Mukhamedov A., Kim Y., Lee Y., et al. Bone health in pediatric patients with neurological disorders. Ann. Pediatr. Endocrinol. Metab. 2020; 25(1): 15-23. https://doi.org/10.6065/apem.2020.25.1.15
Nurković J.S., Petković P., Tiosavljević D., Vojinović R. Measurement of bone mineral density in children with cerebral palsy from an ethical issue to a diagnostic necessity. Biomed. Res.Int. 2020; 2020: 7282946. https://doi.org/10.1155/2020/7282946
Moghadam N., Teimouri A., Khajeh A., Hoseini S. Bone metabolism disorder in epileptic children. Iran. J. Child Neurol. 2018; 12(2): 17-24.
Miziak B., Chrościńska-Krawczyk M., Czuczwar S. An update on the problem of osteoporosis in people with epilepsy taking antiepileptic drugs. Expert Opin. Drug Saf. 2019; 18(8): 679-89. https://doi.org/10.1080/14740338.2019.1625887
Finbråten A.K., Syversen U., Skranes J., Andersen G.L., Stevenson R.D., Vik T. Bone mineral density and vitamin D status in ambulatory and non-ambulatory children with cerebral palsy. Osteoporos.Int. 2015; 26(1): 141-50. https://doi.org/10.1007/s00198-014-2840-0
Iorgi N., Maruca K., Patti G., Mora S. Update on bone density measurements and their interpretation in children and adolescents. Best Pract. Res. Clin. Endocrinol. Metab. 2018; 32(4): 477-98. https://doi.org/10.1016/j.beem.2018.06.002
Albaghdadi O., Alhalabi M., Alourfi Z., Youssef L. Bone health and vitamin D status in young epilepsy patients on valproate monotherapy. Clin. Neurol. Neurosurg. 2016; 146: 52-6. https://doi.org/10.1016/j.clineuro.2016.04.019
Likasitthananon N., Nabangchang C., Simasathien T., Vichutavate S., Phatarakijnirund V., Suwanpakdee P. Hypovitaminosis D and risk factors in pediatric epilepsy children. BMC Pediatr. 2021; 21(1): 432. https://doi.org/10.1186/s12887-021-02906-7
Bell K.L., Benfer K.A., Ware R.S., Patrao T.A., Garvey J.J., Arvedson J.C., et al. Development and validation of a screening tool for feeding/swallowing difficulties and undernutrition in children with cerebral palsy. Dev. Med. Child Neurol. 2019; 61(10): 1175-81. https://doi.org/10.1111/dmcn.14220
Sees J., Sitoula P., Dabney K., Holmes L. Jr., Rogers K.J., Kecskemethy H.H., et al. Pamidronate treatment to prevent reoccurring fractures in children with cerebral palsy. J. Pediatr. Orthop. 2016; 36(2): 193-7. https://doi.org/10.1097/BPO.0000000000000421
Marrani E., Giani T., Simonini G., Cimaz R. Pediatric osteoporosis: diagnosis and treatment considerations. Drugs. 2017; 77(6): 679-95. https://doi.org/10.1007/s40265-017-0715-3
Song L. Calcium and bone metabolism indices. Adv. Clin. Chem. 2017; 82: 1-46. https://doi.org/10.1016/bs.acc.2017.06.005
Vasikaran S., Eastell R., Bruyere O., Foldes A., Garnero P., Griesmacher A. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos.Int. 2011; 22(2): 391-420. https://doi.org/10.1007/s00198-010-1501-1
Wheater G., Elshahaly M., Tuck S., Datta H., Van Laar J. The clinical utility of bone marker measurements in osteoporosis. J. Transl. Med. 2013; 11: 201. https://doi.org/10.1186/1479-5876-11-201
Кенис В.М., Богданова С.Л., Прокопенко Т.Н., Сапоговский А.В., Киселева Т.И. Биомаркеры метаболизма костной ткани у детей с церебральным параличом, способных к передвижению. Ортопедия, травматология и восстановительная хирургия детского возраста. 2019; 7(4): 79-86. https://doi.org/10.17816/PTORS7479-86
Смирнов И.Е., Рошаль Л.М., Кучеренко А.Г., Карасева О.В., Понина И.В. Изменения содержания костных биомаркеров и цитокинов в сыворотке крови при сочетанной травме у детей. Российский педиатрический журнал. 2017; 20(6): 371-8. https://doi.org/10.18821/1560-9561-2017-20-6-371-378
Sakai T., Honzawa S., Kaga M., Iwasaki Y., Masuyama T. Osteoporosis pathology in people with severe motor and intellectual disability. Brain Dev. 2020; 42(3): 256-63. https://doi.org/10.1016/j.braindev.2019.12.010
Lewiecki E.M., Gordon C.M., Baim S., Binkley N., Bilezikian J.P., Kendler D.L., et al. Special report on the 2007 adult and pediatric Position Development Conferences of the International Society for Clinical Densitometry. Osteoporos.Int. 2008; 19(10): 1369-78. https://doi.org/10.1007/s00198-008-0689-9
Арсентьев В.Г., Асеев М.В., Баранов В.С. Исследование минеральной плотности костной ткани у детей и подростков с дисплазиями соединительной ткани. Педиатрия. Журнал им. Г.Н. Сперанского. 2010; 89(5): 73-7
Weber D.R., Boyce A., Gordon C., Högler W., Kecskemethy H.H., Misra M., et al. The utility of DXA assessment at the forearm, proximal femur, and lateral distal femur, and vertebral fracture assessment in the pediatric population: the 2019 official pediatric positions of the ISCD. J. Clin. Densitom. 2019; 22(4): 567-89. https://doi.org/10.1016/j.jocd.2019.07.002
Houlihan C.M., Stevenson R.D. Bone density in cerebral palsy. Phys. Med. Rehabil. Clin. N. Am. 2009; 20(3): 493-508. https://doi.org/10.1016/j.pmr.2009.04.004
Ozel S., Switzer L., Macintosh A., Fehlings D. Informing evidence-based clinical practice guidelines for children with cerebral palsy at risk of osteoporosis: an update. Dev. Med. Child Neurol. 2016; 58(9): 918-23. https://doi.org/10.1111/dmcn.13196
Akhter N., Khan A., Ayyub A. Motor impairment and skeletal mineralization in children with cerebral palsy. J. Pak. Med. Assoc. 2017; 67(2): 200-3.
Crofton P.M., Evans N., Taylor M.R., Holland C.V. Serum CrossLaps: Pediatric reference intervals from birth to 19 years of age. Clin. Chem. 2002; 48(4): 671-3.
Смирнова Г.И., Румянцев Р.Е. Витамин D и аллергические болезни у детей. Российский педиатрический журнал. 2017; 20(3): 166-72. https://doi.org/10.18821/1560-9561-2017-20-3-166-172
Tatay Díaz A., Farrington D.M., Downey Carmona F.J., Macías Moreno M.E., Quintana del Olmo J.J. Bone mineral density in a population with severe infantile cerebral palsy. Rev. Esp. Cir. Ortop. Traumatol. 2012; 56(4): 306-12. https://doi.org/10.1016/j.recot.2012.03.001 (in Spanish)
Gissel T., Poulsen C.S., Vestergaard P. Adverse effects of antiepileptic drugs on bone mineral density in children. Expert Opin. Drug Saf. 2007; 6(3): 267-78. https://doi.org/10.1517/14740338.6.3.267
Petty S.J., O’Brien T.J., Wark J.D. Antiepileptic medication and bone health. Osteoporos.Int. 2007; 18(2): 129-42. https://doi.org/10.1007/s00198-006-0185-z
Suljic E.M., Mehicevic A., Mahmutbegovic N. Effect of long-term carbamazepine therapy on bone health. Med. Arch. 2018; 72(4): 262-6. https://doi.org/10.5455/medarh.2018.72.262-266
Min L., Chunyan W., Biaoxue R. Effects of valproic acid on skeletal metabolism in children with epilepsy: a systematic evaluation and meta-analysis based on 14 studies. BMC Pediatr. 2020; 20(1): 97. https://doi.org/10.1186/s12887-020-1984-7
Tosun A., Erisen Karaca S., Unuvar T., Yurekli Y., Yenisey C., Omurlu I.K. Bone mineral density and vitamin D status in children with epilepsy, cerebral palsy, and cerebral palsy with epilepsy. Childs Nerv. Syst. 2017; 33(1): 153-8. https://doi.org/10.1007/s00381-016-3258-0
Abdullah A.T., Mousheer Z.T. Vitamin D status in epileptic children on valproic acid; a case-control study. Arch. Acad. Emerg. Med. 2020; 8(1): e13.
Verrotti A., Greco R., Latini G., Morgese G., Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia. 2002; 43(12): 1488-92. https://doi.org/10.1046/j.1528-1157.2002.13002.x
Vestergaard P. Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy. Paediatr. Drugs. 2015; 17(2): 141-50. https://doi.org/10.1007/s40272-014-0115-z
Koo D., Hwang K., Han S., Kim J., Joo E., Shin W., et al. Effect of oxcarbazepine on bone mineral density and biochemical markers of bone metabolism in patients with epilepsy. Epilepsy Res. 2014; 108(3): 442-7. https://doi.org/10.1016/j.eplepsyres.2013.09.009
Romano C., Wynckel M., Hulst J., Broekaert I., Bronsky J., Dall’Oglio L., et al. European society for paediatric gastroenterology, hepatology and nutrition guidelines for the evaluation and treatment of gastrointestinal and nutritional complications in children with neurological impairment. J. Pediatr. Gastroenterol. Nutr. 2017; 65(2): 242-64. https://doi.org/10.1097/MPG.0000000000001646
Penagini F., Mameli C., Fabiano V., Brunetti D., Dilillo D., Zuccotti G.V. Dietary intakes and nutritional issues in neurologically impaired children. Nutrients. 2015; 7(11): 9400-15. https://doi.org/10.3390/nu7115469.59